Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
New Merck Debt Totals $8bn; ImmunoGen Raises $297.5m
Executive Summary
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
You may also be interested in...
Finance Watch: Five More Small IPOs Squeeze Through The US Window
Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m.
BeiGene Switches To Combo Therapy Approach For Brukinsa
BeiGene exec reveals Chinese firm's changing development strategy around key asset as further clinical results emerge.
BenevolentAI Goes Public In Europe’s Largest SPAC
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.